About Oncology Biosimilars
Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.
TechNavio's analysts forecast the Global Oncology Biosimilars market to grow at a CAGR of 29.87 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Oncology Biosimilars market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales biosimilars used in cancer treatment.
TechNavio's report, Global Oncology Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Oncology Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Biocon
• Celltrion
• Dr. Reddy's Laboratories
• Hospira
• Mylan
• Sandoz
Other Prominent Vendors
• 3SBio
• Abbvie
• AstraZeneca
• BioXpress Therapeutics
• Boehringer Ingelheim
• Coherus Biosciences
• Intas Pharmaceuticals
• Merck Serono
• Pfizer
• Wockhardt
Market Driver
• Increased Number of Patent Expirations
• For a full, detailed list, view our report
Market Challenge
• Risks Related to Drug Failure
• For a full, detailed list, view our report
Market Trend
• Outsourcing of Biosimilar Manufacturing
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Segmentation by Application
07.1 Cancer Treatment Drugs
07.2 Supportive Care Drugs
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 Biocon
17.1.1 Key Facts
17.1.2 Business Overview
17.1.3 Business Segmentation by Revenue 2014
17.1.4 Business Segmentation by Revenue 2013 and 2014
17.1.5 Recent Developments
17.1.6 SWOT Analysis
17.2 Celltrion
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Product Segmentation
17.2.4 Business Strategy
17.2.5 Recent Developments
17.2.6 SWOT Analysis
17.3 Dr. Reddy's Laboratories
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Business Segmentation by Revenue 2014
17.3.4 Business Segmentation by Revenue 2013 and 2014
17.3.5 Geographical Segmentation by Revenue 2014
17.3.6 Business Strategy
17.3.7 Recent Developments
17.3.8 SWOT Analysis
17.4 Hospira
17.4.1 Key Facts
17.4.2 Business Overview
17.4.3 Business Segmentation by Revenue 2013
17.4.4 Business Segmentation by Revenue 2012 and 2013
17.4.5 Geographical Segmentation by Revenue 2013
17.4.6 Business Strategy
17.4.7 Recent Developments
17.4.8 SWOT Analysis
17.5 Mylan
17.5.1 Key Facts
17.5.2 Business Overview
17.5.3 Business Segmentation by Revenue 2013
17.5.4 Business Segmentation by Revenue 2011-2013
17.5.5 Geographical Segmentation by Revenue 2013
17.5.6 Business Strategy
17.5.7 Recent Developments
17.5.8 SWOT Analysis
17.6 Sandoz
17.6.1 Key Facts
17.6.2 Business Overview
17.6.3 Product Segmentation
17.6.4 Business Strategy
17.6.5 Recent Developments
17.6.6 SWOT Analysis
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Oncology Biosimilars Market 2013-2018 (US$ million)
Exhibit 3: Oncology Biosimilar Drug Segmentation by Application
Exhibit 4: Global Oncology Biosimilars Market by Geographical Segmentation 2013
Exhibit 5: Biocon: Business Segmentation by Revenue 2014
Exhibit 6: Biocon: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 7: Celltrion: Product Segmentation 2013
Exhibit 8: Global Oncology Biosimilars market: Business Segmentation by Revenue 2014
Exhibit 9: Global Oncology Biosimilars market: Business Segmentation by Revenue 2013 and 2014 (US$ billion)
Exhibit 10: Dr. Reddy's Laboratories: Geographical Segmentation by Revenue 2014
Exhibit 11: Global Oncology Biosimilars market: Business Segmentation by Revenue 2013
Exhibit 12: Global Oncology Biosimilars market: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 13: Global Oncology Biosimilars market: Geographical Segmentation by Revenue 2013
Exhibit 14: Global Oncology Biosimilars market: Business Segmentation by Revenue 2013
Exhibit 15: Global Oncology Biosimilars market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 16: Global Oncology Biosimilars market: Geographical Segmentation by Revenue 2013
Exhibit 17: Sandoz: Product Segmentation 2013
